Nick Szubiak MSW LCSW Director Clinical Excellence in Addictions National Council for Behavioral Health Objectives Understand why and how Medication Assisted Treatment works and why we dont use it by challenging the way we view judge and think about addiction ID: 753992
Download Presentation The PPT/PDF document "The Fundamentals of Medication Assisted ..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
The Fundamentals of Medication Assisted Treatment
Nick Szubiak, MSW, LCSW
Director, Clinical Excellence in Addictions
National Council for Behavioral HealthSlide2
Objectives
Understand why and how Medication Assisted Treatment works and why we don't use it by challenging the way we view, judge and think about addiction.
Gain an understanding and recognition of the discrimination and bias that impacts access to evidenced based care for those who need treatment for substance use disorders.
Participants
will identify and describe three differences between integrated MAT treatment practices versus non-integrated MAT treatment practices.
Participants
will list and describe three common barriers to access MAT and identify strategies to increase access to care.Slide3
National Opioid Overdose Epidemic as of 2015
Drug overdose is the leading cause of accidental death in the US, with 52,404 lethal drug overdoses in
Opioid addiction is driving this epidemic, with 20,101 overdose deaths related to prescription pain relievers, and 12,990 overdose deaths related to heroin
From 1999 to 2008, overdose death rates, sales and substance use disorder treatment admissions related to prescription pain relievers increased in parallel.
overdose death rate in 2008 was nearly four times the 1999 rate;
sales of prescription pain relievers in 2010 were four times those in 1999;
substance use disorder treatment admission rate in 2009 was six times the 1999 rateSlide4
National Opioid Overdose Epidemic as of 2015
In 2012, 259 million prescriptions were written for opioids, which is more than enough to give every American adult their own bottle of pills.
Four in five new heroin users started out misusing prescription painkillers.
94% of respondents in a 2014 survey of people in treatment for opioid addiction said they chose to use heroin because prescription opioids were “far more expensive and harder to obtain.”Slide5
Overdose Deaths
Warner et al.
National Vital Statistics Report,
2016;65(10).
Conclusion:
Rising rate of overdose deaths is driven largely by Heroin and Fentanyl Slide6
Origins of Opioid Crisis
Opioids Myth: Non-Addictive
Porter and Jick letter published in New England Journal of Medicine in 1980; frequently cited in marketing of new synthetic opioids
OxyContin brought to market in 1996
History of Untreated Pain
Pain was left untreated even for terminally-ill cancer patients
Doctors were weary of prescribing opioid medications
Pain As 5
th
vital sign
National initiative rolled out in the late 90s
Emergence of Pill Mills
Unrestricted prescribing of pain medications
Unlike legitimate pain clinics, pill mills see greater numbers of patients, write more prescription, and do less medical exams. Most are cash-only. Greater availability of heroinLarger, cheaper supply and more potent than prescription painkillersLeading Cause of Accidental Death Starting in 2008, drug overdoses became the leading cause of injury death in the United States surpassing car accidents and firearmsSlide7
Stigma and Discrimination
Stigma refers to
negative stereotypes
Discrimination is the
behavior that results
from the negative stereotype
Discrimination in this case means treating someone less favorably than someone else because he or she has a disability
Would you treat someone less favorably because they were prescribed insulin for diabetes? What about people with high-cholesterol who are prescribed cholesterol-lowering medication?Slide8
Beliefs PerceptionsSlide9
How has our definition of addiction changed?
Addiction was thought of as a
moral failing
or
character defect
Drug use: criminal issue vs. health issue
Language matters: move away from
“addicts”
Scientific research has demonstrated that, whether we are aware of it, the use of certain terms implicitly generate biases that can influence the formation and effectiveness of our social and public health policies in addressing them Slide10Slide11
Excessive amounts used
Excessive time spent using/obtaining
Tolerance
Withdrawal
Cravings or urges to use
Unsuccessful attempts to cut down
- Hazardous use
Health problems
Missed obligations
Interference with activities
Personal problems
Three Stages of AddictionSlide12
SUD is a complex disease that results in chemical and physiologic changes to the brain
SUD must be treated like any other chronic, relapsing condition
Slide from C. Cynthia Reilly, MS, BS Pharm
Director, Substance Use Prevention and Treatment Initiative
The Pew Charitable Trusts
Reily
www.nida.govSlide13
Defining Addiction
Addiction is a primary, chronic
disease
Biological
Psychological
Social
Components
Primary Disease
- meaning that it’s not the result of other causes such as emotional or psychiatric problems.
Chronic Disease
- like cardiovascular disease or diabetes it must be treated, managed and monitored over a life‐time. Slide14
“At its core, addiction isn’t just a social problem or a moral problem or a criminal problem. It’s a
brain problem
whose behaviors manifest in all these other areas. “
Many behaviors driven by addiction are real problems and sometimes criminal acts. But the disease is about brains, not drugs. It’s about underlying neurology, not outward actions.”
- Dr. Michael Miller, ASAMSlide15
Defining Addiction
Addiction is a primary, chronic and relapsing brain disease characterized by an individual pathologically pursuing reward and/or relief by substance use and other behaviors
- ASAMSlide16
Beliefs PerceptionsSlide17
How has addiction treatment changed?
Short-term acute
interventions vs.
chronic disease
management model
Relapse is a part of the disease,
NOT
a failure
Similar to other chronic diseases, addiction often involves cycles of relapse and remission
Without treatment or engagement in recovery activities, addiction is progressive and can result in disability or premature deathSlide18
Welcome MAT
Medications
Recovery Work
Intensive Psycho, Social and Behavioral treatmentsSlide19
OUD Drugs: Distinct Pharmacology and Roles in Treatment
http://www.pewtrusts.org/en/research-and-analysis/fact-sheets/2016/11/medication-assisted-treatment-improves-outcomes-for-patients-with-opioid-use-disorderSlide20
The Case for MAT
MAT is “the use of medications, in combination with counseling and behavioral therapies, to provide a whole-patient approach to the treatment of substance use disorders.”--SAMHSA
Research indicates that
methadone
and
buprenorphine
have a strong evidence base supporting their clinical effectiveness. Strong support for
Vivitrol
.
MAT is the
gold standard
for opioid use disorder (OUD) treatment:
Reduces drug use
Reduces risk of overdose
Prevents injection behaviors
Reduces criminal behaviorSlide21
MAT Supports Recovery
persistent intentional
abstinence
from intoxication
engagement
in daily life
gaining
employment
reestablish
family and social ties
being
present
in everyday life
being able to weather the challenges, daily lows and highs of life without substances as an external coping skills that has negative side effects and consequences Slide22
An Unmet Need
20.2 Million People Have SUD
2 million had a substance use disorder involving prescription pain relievers and 591,000 had a substance use disorder involving heroin
10% to 40% of individuals with addictions receive treatment
Only a fraction of those that get treatment get MAT
300,000-400,000 people on methadone in a given year
40,000 on buprenorphine
5-10,000 on Naltrexone
Only
10%
of the people who need to be on MAT for opioid use disorder (OUC) are receiving it
More than
two-thirds
of U.S. clinics and treatment centers still do not offer MAT medications (Stateline, 2016)Slide23
Evidenced Based- Utilization
Slide24
The Bias Against MAT
Belief
that use of medication conflicts with abstinence-based treatment programs like 12-step programs*
*Not all 12-step programs prohibit MAT and mutual support groups remain an important part of addiction treatment and recovery. Slide25
The Bias Against MAT
Belief
that abstinence is more effective than MAT
Many people, including individuals who have worked in the treatment field, have recovered from addiction without the use of medicationsSlide26
The Bias Against MAT
Perception
that MAT is not treating the underlying causes of addiction. Slide27
The Bias Against MAT
Negative
perceptions
around methadone clinics; patients may try to limit their time thereSlide28
The Bias Against MAT
Belief
that people on MAT are not in recovery; not “clean”Slide29
The Bias Against MAT
Belief
that MAT is a substitution of one drug for the other; fighting fire with fireSlide30
The Bias Against MAT
Belief
that opioid use is not in my scope an should be treated by specialty addiction providersSlide31
There is no evidence to support stopping MAT
95% of methadone patients do not achieve abstinence when attempting to taper off (Nosyk, et al. 2013)
Over 90% of buprenorphine patients relapse within 8 weeks of taper completion (Weiss, et al. 2011)
Successful patients are commonly maintained on
Methadone for 24+ months, Buprenorphine for 18+ months
Typically patients with continuous sobriety for 1-2+ years have the best outcomes
Treatment <6 months has worse outcomes
Stopping/Tapering MAT Slide32
VERDICT
Bias against MAT is deadly
Leading Cause of Accidental Death
Starting in 2008
, drug overdoses became the leading cause of injury death in the United States surpassing car accidents and firearmsSlide33
Sound Familiar?
Similar to the 1990s with patients who had suicidal depression and were being judged for taking Prozac Slide34
Patient Impact
Neglected a full range of treatment options
Pressure from child welfare, jail, prison, and parole/probation systems to stop MAT
Restricted access
to recovery support services
For example, many recovery houses do not allow residents to be on MAT
The previous two points can lead patients stop MAT before it is clinically appropriateSlide35
Biases within MAT
Methadone and buprenorphine are narcotics
Bias towards using Vivitrol because it is “safer”
Diversion of methadone and buprenorphine
Used to get “high” and street value
“Addiction doctors agree that all three medications should be available to patients, because one may be more effective than another, depending in part on the person’s age, length of time as an addict
, home and work environment and underlying mental health issues. The American Medical Association, the American Academy of Addiction Psychiatry and the American Society of Addiction Medicine unequivocally support their use.” (Stateline, 2016)Slide36
MAT Methadone Bias
Treating and opioid with an opioid? Fire with Fire?
Overdose trends in the US: Long acting or extended release
Methadone is long acting – stays in your system 24-36 hours but the pain control or analgesia only lasts 6-8 hours
Pain management vs OUD treatment
Talking about pill form vs liquid form
Observed in clinic vs pills taken in the community (diversion) Slide37
3 P’s: Providers, Perceptions, Payment
Perceptions: The perceptions of MAT and its value among patients, practitioners, and institutions
Some practitioners do not believe that MAT is more effective than abstinence-based treatment—when patients are treated without medication—despite science-based evidence
Providers: The availability of qualified practitioners and their capacity to meet patient demand for MAT
Hiring physicians can be expensive for clinics, especially small centers Physicians receive little education in addiction care & are reluctant to extend their practice to patients with addictions
Payment: The availability and limits of insurance coverage for MAT
Few private insurers and state Medicaid programs cover all of the MAT medications approved by the Food and Drug Administration. Other face hurdles such as prior authorization requirements or “fail first” policies. Slide38
How do we impact discrimination
?
Share the evidence!
Recognize MAT for what it is:
The gold standard of OUD treatmentSlide39
Defining Recovery
A process of change through which individuals improve their health and wellness, live a self-directed life, and strive to reach their full potential.Slide40
What is recovery?
A process of change through which individuals improve their health and wellness, live a self-directed life, and strive to reach their full potential.
Health
: overcoming or managing one’s disease(s) or symptoms—for example, abstaining from use of alcohol, illicit drugs, and non-prescribed medications if one has an addiction problem—and for everyone in recovery, making informed, healthy choices that support physical and emotional wellbeing.
Home:
a stable and safe place to live;
Purpose:
meaningful daily activities, such as a job, school, volunteerism, family caretaking, or creative endeavors, and the independence, income and resources to participate in society; and
Community
: relationships and social networks that provide support, friendship, love, and hope.
https://blog.samhsa.gov/2012/03/23/defintion-of-recovery-updated/#.WLY7_TvytPYSlide41
What is recovery?
Persistent intentional abstinence from intoxication
Engagement in daily life
Gaining employment
Re-establish family and social ties
Being present in everyday life
Being able to weather the challenges, daily lows and highs of life without using substances as an external coping skills that has negative side effects and consequences Slide42
Embracing Many Pathways to Recovery
All patients are offered MAT: Methadone, Buprenorphine, Naltrexone
Patient Centered Care: All patients have an option of any of the three medications to treat SUD. There are pros and cons to each. There should be consideration of where they are in life, phase of treatment, and what the patient needs
Treatment works better with patient buy-inSlide43
The Fundamentals of Medication Assisted Treatment:
An Integrated Approach to Recovery for Individuals with Co-Occurring Disorders
Angele Moss-Baker, LPC, LMFT, MAC, EAS-C
Comprehensive Addiction & Psychological Services, LLCSlide44
Traditional Approaches to Treatment
Sequential treatment -
The client is treated in one system, then the Agencies work largely independent of each other.
Parallel model –
The client is treated simultaneously, but by two separate agencies. The patient participates in two systems simultaneously. Coordination is not consistent.
44Slide45
Falling Through the Cracks
45Slide46Slide47
2015: Co-Occurring Mental Health and Substance Use – Adults
47
SUD and Mental Illness
SUD,
No Mental
Illness
11.5 Million
19.6 Million
Had SUD
8.1
Million
35.4
Million
43.4 Million Had Mental Illness
Mental Illness,
No SUD
Results from 2015 National Survey on Drug Use and HealthSlide48
Comorbidities and MAT
Psychiatric Comorbidity
The most common are: Major Depression, Anxiety, Bipolar, PTSD.
Psychiatric comorbidities may complicate buprenorphine treatment.
NOTE:
C
ombining medications used in MAT with anxiety treatment medications can be fatal. Benzodiazepines are highly associated with overdose fatalities when combined with opioids.
Medical Comorbidity
The most common are: HIV, Hepatitis B and C, Tuberculosis, Syphilis.
MAT and drug interactions - antiretroviral medications, vital hepatitis medical treatment.Slide49
Which Comes First?
49Slide50Slide51
Integrated Treatment
An approach that involves simultaneous treatment of both disorders in a setting designed to accommodate both problems in a unified and comprehensive treatment program.
An approach to meet the substance use, medical and mental health, and social needs of a patient
51Slide52
Essential Principles and Competencies for COD and MAT
Integrated Treatment
or highly coordinated when not on site.
Monitor patient progress and compliance with off-site treatment
Staff competency
– Cross training
Co-occurring psychiatric and medical conditions
Psychotropic medications
- prescribed when significant impairment exists.
Prescribing medications with abuse potential such as benzodiazepines (opt
Serax
)
All medications are monitored
Alleviate shame and stigma to receive treatment for co-occurring disordersIntensive therapy for those with CODs, than those without CODs.Slide53
Quadrants of MH/SUD Services
Category III
Substance Abuse System
Severe SUD, Mild MI
Med-Monitored IPWM,
PHP, RTF, MAT
DDC/DDE
Category IV
Acute Care Hospitals
Severe MI, Severe SUD
Med-Managed IPWM, IP Psych, Residential
Category I
Primary Health Care
Mild MI, Mild SUD
PCP, OP, IOP
Category II
Mental Health System
Severe MI, Mild SUD
OP, IOP, PHP, ACT, GH
53
Alcohol and other drugs
High Intensity
Low Intensity
High Intensity
Mental IllnessSlide54
ASAM Treatment Levels of Service
Level III
Med-Monitored IPWM
Clinically-Managed Residential WM
Medically-Monitored Intensive Inpatient
Clinically-Managed High-Intensity Residential
Clinically Managed Population-Specific High Intensity Residential Services
Clinically-Managed Low-Intensity Residential
Level IV
Med-Managed IPWM
Medically-Managed Intensive Inpatient
Level I
Ambulatory Withdrawal Management without Extended On-Site Monitoring
Outpatient Services
Level 0.5
Early Intervention
Level II
Ambulatory WM with Extended On-Site Monitoring
Partial Hospitalization
Intensive Outpatient
OPIOID TREATMENT SERVICES (OTS)
Opioid
Treatment Program (OTP) – Agonist meds: methadone,
buprenorphine
;
Office Based
Opioid
Treatment (OBOT) Antagonist medication –
naltrexone
54Slide55
ASAM Practice Guideline for the Treatment of Co-Occurring Psychiatric Disorders
A comprehensive assessment
including determination of mental health status should evaluate whether the patient is stable.
Patients with suicidal or homicidal ideation should be referred immediately for treatment and possibly hospitalization.
Reduce, manage, and monitor suicide risk
Management
of patients at risk for suicide should include:
reducing immediate risk
managing underlying factors associated with suicidal intent
monitoring and follow-up
Assessment for psychiatric disorder
should occur at the onset of agonist or antagonist treatment.
Reassessment using a detailed mental status examination should occur after stabilization with methadone,
buprenorphine or naltrexone. Pharmacotherapy in conjunction with psychosocial treatment should be considered for patients with opioid use disorder and a co-occurring psychiatric disorder.Slide56
Quadrant of Care:
Where Does Treatment Begin?
Patients in acute psychiatric danger –
Patients presenting with suicidal or homicidal ideation or threats, that may interfere with their safety and ability to function should be assessed and treated immediately whether resulting from:
acute intoxication or withdrawal, or
an independent co-occurring disorder or substance-induced disorder
Although their symptoms may be short lived, admission to a psychiatric unit for brief treatment may be necessary if outpatient care is too risky or problematic.
Immediate administration of antipsychotic drugs, benzodiazepines, or other sedatives may be required to establish behavioral control.
A physician, physician's assistant, or nurse practitioner on staff can prescribe medications at the OTP.Slide57
Quadrant of Care:
Where Does Treatment Begin?
Patients with established severe co-occurring disorders who are not in acute danger
Should receive medication with the lowest abuse potential for their condition.
If an OTP is staffed appropriately and prepared to treat patients with severe co-occurring disorders, these patients can be treated on site.
If there is no such OTP, patients may need to remain in a less optimal OTP but receive psychiatric treatment at another facility with effective highly collaborative communication between OTPs and mental health providers to coordinate treatment.Slide58
Quadrant of Care:
Where Does Treatment Begin?
Patients with less severe, persisting or emerging symptoms of co-occurring disorders.
Patients in MAT with non-disabling symptoms of less severe co-occurring disorders (e.g., mood, anxiety, and personality disorders) should continue or begin medication, psychotherapy, or both for their co-occurring disorders.
These patients should continue in MAT if the OTP is staffed to treat them. Slide59
Quadrant of Care:
Where Does Treatment Begin?
Patients with less severe, presumptively substance-induced co-occurring disorders.
Patients in MAT with symptoms of a psychiatric disorder, without a history of CODs, receive no new psychotropic medications until they are stabilized on MAT - because their symptoms might remit or significantly diminish after a period of substance abuse treatment.
Exceptions include patients who have acute, substance-induced disorders such as extreme anxiety or paranoia that are likely to be transitory but require temporary sedation or antianxiety medication. Slide60
Effective Integrated Service Delivery
Based on principles of effective integrated service delivery:
Collaboration and Coordinated Care
42 CFR § 2 - CONFIDENTIALITY OF SUBSTANCE USE DISORDER PATIENT RECORDS
Motivational Interviewing
Stage-Wise TreatmentSlide61
Effective Integrated Service Delivery
With Psychiatric Providers
With MAT Physician
With Primary Care and other medical providers
Coordinating with Specialty Providers
Empathic
Nonjudgmental
Roll with Resistance
Precontemplation
Contemplation
Preparation
Action
Maintenance
Collaboration/Coordinated
Care
Motivational
Interviewing
Stage-Wise
TreatmentSlide62
References
Medication Assisted Treatment: A Standard of Care
. Elinore
McCance
-Katz, SAMHSA 2014.
A Family Guide to Concurrent Disorders.
Centre for Addiction and Mental Health.
Integrated Service Delivery Models for Opioid Treatment Programs in an Era of Increasing Opioid Addiction, Health Reform, and Parity.
Kenneth B.
Stoller
, Mary Ann C. Stephens, Allegra
Schorr
. American Association for the Treatment of Opioid Dependence, July 2015.
Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs: TIP 43. SAMHSA 2012.Federal Guidelines for Opioid Treatment Programs. SAMHSA January 2015.The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use. American Society of Addiction Medicine. (2013). The ASAM Criteria: Treatment Criteria for Addictive, Substance-Related, and Co-occurring ConditionsSlide63
Thank You!
Angele Moss-Baker
Comprehensive Addiction & Psychological Services, LLC
Caps.therapy@yahoo.com
www.caps-therapy.comSlide64
Policy Interventions
Affordable Care Act/Medicaid expansion
Individuals with mental health and substance use disorders were the single largest beneficiaries of Medicaid expansion with
nearly one-third of new Medicaid enrollees having a either a mental health and/or Substance Use Disorder
Physician Buprenorphine Prescribing Limit Raised to 275 Patients
June 2016 SAMHSA raised doctor prescribing limit from 100 to 275 patients
Comprehensive Addiction & Recovery Act (CARA)
Allows Nurse Practitioners and Physician Assistants to prescribe buprenorphine for up to 30 patients
First addiction bill passed through Congress in 40 years
21st Century Cures Act
Allocated $1 billion in State Targeted Response grants to curb opioid abuse and increase treatment capacity
Surgeon General Report
First Surgeon General report on addictionSlide65
Resources on Opioid Use
Centers for Disease Control and Prevention
Overdose Data
Guidelines for Prescribing Opioids for Chronic Pain
Substance Abuse and Mental Health Services Agency
Data on
Prescription Opioid and Heroin Use
from the annual National Survey on Drug Use and Health
Medication-Assisted Treatment
Information on certification, oversight, DATA-2000 waivers, legislation, regulation, and more
Office on National Drug Control Policy
(
archived website
)
National Drug Control Strategy
Data
on Methadone, Buprenorphine treatment and drug poisoning deaths
National Institutes on Drug Abuse
Opioid Epidemic Strategies & ResourcesSlide66
https://www.thenationalcouncil.org/mat/Slide67
Funding for this initiative was made possible (in part) by Providers’ Clinical Support System for Medication Assisted Treatment (grant no. 5U79TI024697) from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
PCSS-MAT
is a collaborative effort led by
American Academy of Addiction Psychiatry
in partnership with:
American Osteopathic Academy of Addiction Medicine
,
American Psychiatric Association
,
American Society of Addiction Medicine
and
Association for Medical Education and Research in Substance Abuse
.
For more information visit:
www.pcssmat.org
For questions email:
pcssmat@aaap
.org
Twitter:
@
PCSSProjectsSlide68
Treatment Works, People Recover
Research shows that the earlier drug use begins, the more likely it will progress to addiction | Teen alcohol and drug use is declining
More and more individuals are engaged in MAT
Over 23 million Americans are in recovery from addiction to alcohol and other drugsSlide69
References
1 National Institute on Drug Abuse. (2015). Drugs of Abuse: Opioids. Bethesda, MD: National Institute on Drug Abuse. Available at http://www.drugabuse.gov/drugs-abuse/opioids.
2 American Society of Addiction Medicine. (2011). Public Policy Statement: Definition of Addiction. Chevy Chase, MD: American Society of Addiction Medicine. Available at http://www.asam.org/docs/publicypolicy-statements/1definition_of_addiction_long_4-11.pdf?sfvrsn=2.
3 Center for Behavioral Health Statistics and Quality. (2016). Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health (HHS Publication No. SMA 16-4984, NSDUH Series H-51). Retrieved from http://www.samhsa.gov/data/.
4 National Institute on Drug Abuse. (2014). Drug Facts: Heroin. Bethesda, MD: National Institute on Drug Abuse. Available at http://www.drugabuse.gov/publications/drugfacts/heroin.
5 Rudd RA, Seth P, David F, Scholl L. Increases in Drug and Opioid-Involved Overdose Deaths — United States, 2010–2015. MMWR
Morb
Mortal
Wkly
Rep 2016;65:1445–1452. DOI: http://dx.doi.org/10.15585/mmwr.mm655051e1Slide70
Thank You!
Nick Szubiak, MSW, LCSW
Integrated Health Consultant
Director, Clinical Excellence in Addictions
National Council for Behavioral Health
LinkedIn: Nick Szubiak, MSW,LCSW
Twitter: @
nszubiak
nicks@thenationalcouncil.org
Office
202.621.1625
C.
808.895.7679